Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

@article{Yokota2008EfficacyAS,
  title={Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial},
  author={Shumpei Yokota and Tomoyuki Imagawa and Masaaki Mori and Takako Miyamae and Yukoh Aihara and Shuji Takei and Naomi Iwata and Hiroaki Umebayashi and Takuji Murata and Mari Miyoshi and Minako Tomiita and Norihiro Nishimoto and Tadamitsu Kishimoto},
  journal={The Lancet},
  year={2008},
  volume={371},
  pages={998-1006}
}
Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial
TLDR
The study suggests that tocilizumab is effective in adult-onset Still’s disease, although the primary endpoint was not met and solid conclusion was not drawn.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
TLDR
Tocilizumab was efficacious in severe, persistent systemic JIA and adverse events were common and included infection, neutropenia, and increased aminotransferase levels.
Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan
TLDR
The long-term efficacy and safety of treatment through 144 weeks are presented and patients responding to tocilizumab and needing further treatment entered the open-label extension.
Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan
TLDR
TCZ has demonstrated durability of effectiveness in the longterm treatment of children with sJIA and has shown good tolerability and a low discontinuation rate associated with AE, development of anti-TCZ antibodies, or inadequate response.
Clinically inactive disease status with tocilizumab every 4 weeks in refractory systemic-onset juvenile idiopathic arthritis
TLDR
It is concluded that 8 mg/kg every 4 weeks was a suitable dosage for tocilizumab in refractory SoJIA in developing countries, based on effectiveness, safety, and financial factors.
Is tocilizumab an option for the treatment of arthritis?
TLDR
Provided long-term safety can be established, tocilizumab will probably become part of the treatment for rheumatoid arthritis and may become a major breakthrough for the treatment of systemic-onset juvenile idiopathic arthritis.
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
TLDR
Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort of children with systemic juvenile idiopathic arthritis and active systemic features and further studies in a larger population ofChildren with systemic JIA are warranted.
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
TLDR
Anakinra treatment is effective in SJIA, at least in the short term, and is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature.
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis
TLDR
Tocilizumab showed early and sustained efficacy and tolerability for treating intractable pJIA, which suggests that it is a promising new treatment for this disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
TLDR
MRA treatment of children with active systemic disease results in clinical improvement and in normalized levels of acute-phase reactants, and provided greater clinical benefit than conventional corticosteroids, considering the ill effects of IL-6 and adverse events.
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
TLDR
Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis and is well tolerated by pediatric patients.
Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
TLDR
MTX 15-20 mg/m2 given orally once a week was found to be an effective treatment for both extended oligoarticular and systemic JIA in this shortterm trial and long-term efficacy needs to be addressed in future studies.
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
TLDR
Although most patients initially respond to etanercept, this initial response is not always followed by sustained improvement over longer periods of time, and the higher rate of treatment failure in the group with systemic-onset JIA indicates that these patients in particular may require alternative treatments.
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
TLDR
Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
TLDR
The use of the recombinant interleukin 1 receptor antagonist anakinra is described in 2 patients with therapy resistant SOJRA, both patients experienced immediate and sustained resolution of symptoms and laboratory markers of inflammation.
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
TLDR
It is shown that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs), and that this cytokine represents a target for therapy in this disease.
Macrophage activation syndrome in juvenile idiopathic arthritis.
TLDR
The data, together with a similar, published observation, suggest that the TNF inhibitor etanercept is potentially useful for obtaining remission in children not responding to steroids and cyclosporin A.
Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases.
TLDR
It must be borne in mind that children with rheumatic diseases, especially the systemic form of juvenile chronic arthritis, are highly vulnerable to life-threatening macrophage activation, which appears to be more frequent than previously recognized.
...
1
2
3
...